RU2312661C2 - Применение циклопамина при лечении псориаза - Google Patents

Применение циклопамина при лечении псориаза Download PDF

Info

Publication number
RU2312661C2
RU2312661C2 RU2004103074/15A RU2004103074A RU2312661C2 RU 2312661 C2 RU2312661 C2 RU 2312661C2 RU 2004103074/15 A RU2004103074/15 A RU 2004103074/15A RU 2004103074 A RU2004103074 A RU 2004103074A RU 2312661 C2 RU2312661 C2 RU 2312661C2
Authority
RU
Russia
Prior art keywords
cyclopamine
skin
psoriatic
shows
lesion
Prior art date
Application number
RU2004103074/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004103074A (ru
Inventor
Шинан ТАШ (TR)
Шинан ТАШ
Октай АВСИ (TR)
Октай АВСИ
Original Assignee
Шинан ТАШ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2312661(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шинан ТАШ filed Critical Шинан ТАШ
Publication of RU2004103074A publication Critical patent/RU2004103074A/ru
Application granted granted Critical
Publication of RU2312661C2 publication Critical patent/RU2312661C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2004103074/15A 2001-07-02 2002-04-19 Применение циклопамина при лечении псориаза RU2312661C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
TRPCT/TR01/00027 2001-07-02

Publications (2)

Publication Number Publication Date
RU2004103074A RU2004103074A (ru) 2005-05-10
RU2312661C2 true RU2312661C2 (ru) 2007-12-20

Family

ID=21619326

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004103074/15A RU2312661C2 (ru) 2001-07-02 2002-04-19 Применение циклопамина при лечении псориаза

Country Status (14)

Country Link
EP (4) EP2862570A1 (enExample)
JP (3) JP2004536045A (enExample)
KR (1) KR20090125833A (enExample)
CN (2) CN1525859B (enExample)
AT (2) ATE305300T1 (enExample)
AU (1) AU2001272892B8 (enExample)
BR (1) BR0117063A (enExample)
CA (1) CA2452151C (enExample)
DE (2) DE60113733T2 (enExample)
DK (2) DK1401438T3 (enExample)
ES (3) ES2534400T3 (enExample)
PT (1) PT1411938E (enExample)
RU (1) RU2312661C2 (enExample)
WO (2) WO2002078703A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
AU2006283040B2 (en) 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
MY181496A (en) * 2006-10-31 2020-12-23 Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
NZ579361A (en) * 2007-03-07 2012-04-27 Infinity Discovery Inc Heterocyclic cyclopamine analogs and methods of use thereof
US7964590B2 (en) 2007-03-07 2011-06-21 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
CA3227688A1 (en) 2021-09-13 2023-03-02 Sinan Tas Effective interventions with aging and diseases of aging of human and their consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2000074706A1 (en) * 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
RU2164414C2 (ru) * 1994-06-13 2001-03-27 Биоти Терапиз Корп. Подавление роста опухолевых клеток эктодоменом синдекана-1
WO2001040438A2 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098196B1 (en) * 1999-10-13 2006-08-29 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2164414C2 (ru) * 1994-06-13 2001-03-27 Биоти Терапиз Корп. Подавление роста опухолевых клеток эктодоменом синдекана-1
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2000074706A1 (en) * 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
WO2001040438A2 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Реферат Entrez PubMed Tuting T. The immunology of cutaneous DNA immunization. Curr. Opin. Mol. Ther. 1999 Apr; 1(2):216-25. А.РОЙТ и др. Иммунология. - М.: Мир, 2000, с.335-336, 344-345, реферат Entrez PubMed: Bang К. et al. CD4+ CD8+ (thymocyte-like) Т-lymphocytes present in blood and skin from patients with atopic dermatitis suggest immune dysregulation. Br. J. Dermatol. 2001 Jun; 144(6):1140-7. *

Also Published As

Publication number Publication date
DE60204966T2 (de) 2006-05-18
JP2004536045A (ja) 2004-12-02
CA2452151C (en) 2012-01-03
ATE305300T1 (de) 2005-10-15
DK1401438T3 (da) 2006-02-13
BR0117063A (pt) 2004-07-27
WO2002078704A1 (en) 2002-10-10
EP1561464A3 (en) 2007-04-25
RU2004103074A (ru) 2005-05-10
DE60113733T2 (de) 2006-06-29
AU2001272892B2 (en) 2006-03-16
ES2534400T3 (es) 2015-04-22
DE60204966D1 (de) 2005-08-11
CN1525859B (zh) 2010-05-05
KR20090125833A (ko) 2009-12-07
WO2002078703A1 (en) 2002-10-10
ES2250434T3 (es) 2006-04-16
EP1561464A2 (en) 2005-08-10
PT1411938E (pt) 2005-11-30
AU2001272892B8 (en) 2006-05-04
DK1411938T3 (da) 2005-11-07
EP1401438B1 (en) 2005-09-28
JP2010132691A (ja) 2010-06-17
JP2014028834A (ja) 2014-02-13
EP2216022B1 (en) 2015-01-07
EP2862570A1 (en) 2015-04-22
EP2216022A1 (en) 2010-08-11
CN1525859A (zh) 2004-09-01
DE60113733D1 (de) 2006-02-09
CA2452151A1 (en) 2002-10-10
ES2246011T3 (es) 2006-02-01
WO2002078703A8 (en) 2003-06-12
JP5424923B2 (ja) 2014-02-26
CN1522146A (zh) 2004-08-18
ATE299022T1 (de) 2005-07-15
EP1401438A1 (en) 2004-03-31
CN1230169C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
RU2312661C2 (ru) Применение циклопамина при лечении псориаза
US9757361B2 (en) Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells
CA2866527C (en) Use of isoeugenol esters in treating hyperpigmentation
HU218936B (hu) Stroncium (II) valamely szervetlen sóját tartalmazó bőriritáció elleni hatású topikális gyógyászati készítmények
US20090149536A1 (en) 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
US10869822B2 (en) Compositions for treatment of dermatological diseases and conditions and methods of use thereof
PL186017B1 (pl) Zastosowanie ekstraktu z niefotosyntetyzującej bakterii nitkowatej oraz kompozycja zawierająca takiekstrakt
JP2014503587A (ja) 界面活性剤組成物
JP2008540514A (ja) 過剰増殖表皮疾患の治療用組成物及び方法
MXPA00009705A (es) Uso de poliaminas en el tratamiento de sintomas dermatologicos.
RU2146519C1 (ru) Фармацевтическая композиция на основе антагониста вещества p
JPH08208508A (ja) 皮膚の赤みの治療におけるサブスタンスｐアンタゴニストの使用
Fry Atlas of dermatology
Schalock et al. Lippincott's primary care dermatology
Moglia et al. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses
JP3830963B2 (ja) 乾癬治療
US20180185391A1 (en) Drug Treatment Of Psoriasis And Of Other Skin Disorders Associated With Inhibition Of Differentiation Of Epidermal Cells
JP2024128926A (ja) 顔の皮膚状態の改善剤
CN121152629A (zh) 药物组合物

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110420